ArticleFrontiers in oncology2026
A gastric and pleural metastasis of occult breast lobular cancer in an elderly female and radiomics assisted analysis of a rare metastasis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metastatic breast cancer involving the gastrointestinal tract is rare, particularly in lobular carcinoma, often emerging later in disease progression. Occult primary breast tumors are exceptionally uncommon. This study reports the first case of occult breast lobular carcinoma (OBLC) with concurrent gastric and pleural metastases in a 65-year-old female. Methods: A multidisciplinary diagnostic approach integrated histopathological and radiomic analyses. Immunohistochemical (IHC) profiles of axillary lymph node and gastric lesions were compared. Chest enhanced computed tomography (CT)-based radiomics quantified tumor texture features across five time points (T1-T5: pre- and post-treatment). The patient received aromatase inhibitors (AIs) combined with CDK4/6i as first-line treatment and chemotherapy as second-line treatment. Results: Immunohistochemistry confirmed consistent biomarker expression across metastatic sites, including ER positive, PR negative, HER2 negative and GATA3 positive. However, S100, SALL4, Syn, CDX2 and CgA were all expressed negatively in gastric metastatic lesions. Radiomics revealed progressive tumor brightness peaking at T3 (pre-treatment), followed by significant attenuation post-treatment (T4-T5). The ngtdm_Strength parameter increased markedly at T4-T5, compared to T1-T3, reflecting altered tumor vascularity after therapy. After two lines of treatment, the patient has survived for 24 months. Conclusions: This case highlights OBLC's diagnostic complexity and underscores the role of radiomics in tracking metastatic evolution. Coordinated IHC and CT-based texture analysis aided lesion characterization and treatment monitoring for managing gastric metastases in OBLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.